MindWalk is a biotech and AI company that provides integrated antibody discovery and development services. The company combines wet-lab discovery with LensAI, an AI software platform built on patented HYFT technology. MindWalk Biologics operates a Canadian lab that generates custom antibodies, including monoclonal antibodies and nanobodies, for client discovery campaigns. The LensAI platform provides analytics for target profiling, candidate design, and immunogenicity screening. While MindWalk currently derives most of its revenue from project-based fee-for-service contracts, management is transitioning the business toward a recurring revenue model through LensAI SaaS subscriptions. MindWalk also develops an internal pipeline of proprietary therapeutic candidates, such as GLP-1 receptor agonists and vaccines, intended for future licensing or partnership. To fund these programs without diluting parent company shareholders, MindWalk uses a segregated portfolio structure for asset-level financing. The company is concentrating its growth strategy on the U.S. market, specifically in the Boston-Cambridge area, following the divestiture of its European wet-lab operations. MindWalk states its client base includes 19 of the top 20 global pharmaceutical companies.